177 related articles for article (PubMed ID: 26515754)
1. Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.
Esser AK; Schmieder AH; Ross MH; Xiang J; Su X; Cui G; Zhang H; Yang X; Allen JS; Williams T; Wickline SA; Pan D; Lanza GM; Weilbaecher KN
Nanomedicine; 2016 Jan; 12(1):201-11. PubMed ID: 26515754
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.
Pan D; Schmieder AH; Wang K; Yang X; Senpan A; Cui G; Killgore K; Kim B; Allen JS; Zhang H; Caruthers SD; Shen B; Wickline SA; Lanza GM
Theranostics; 2014; 4(6):565-78. PubMed ID: 24723979
[TBL] [Abstract][Full Text] [Related]
3. Anti-angiogenic Nanotherapy Inhibits Airway Remodeling and Hyper-responsiveness of Dust Mite Triggered Asthma in the Brown Norway Rat.
Lanza GM; Jenkins J; Schmieder AH; Moldobaeva A; Cui G; Zhang H; Yang X; Zhong Q; Keupp J; Sergin I; Paranandi KS; Eldridge L; Allen JS; Williams T; Scott MJ; Razani B; Wagner EM
Theranostics; 2017; 7(2):377-389. PubMed ID: 28042341
[TBL] [Abstract][Full Text] [Related]
4. Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.
Zhou HF; Yan H; Hu Y; Springer LE; Yang X; Wickline SA; Pan D; Lanza GM; Pham CT
ACS Nano; 2014 Jul; 8(7):7305-17. PubMed ID: 24941020
[TBL] [Abstract][Full Text] [Related]
5. Nanotherapy delivery of c-myc inhibitor targets Protumor Macrophages and preserves Antitumor Macrophages in Breast Cancer.
Esser AK; Ross MH; Fontana F; Su X; Gabay A; Fox GC; Xu Y; Xiang J; Schmieder AH; Yang X; Cui G; Scott M; Achilefu S; Chauhan J; Fletcher S; Lanza GM; Weilbaecher KN
Theranostics; 2020; 10(17):7510-7526. PubMed ID: 32685002
[TBL] [Abstract][Full Text] [Related]
6. alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.
Zhang R; Pan D; Cai X; Yang X; Senpan A; Allen JS; Lanza GM; Wang LV
Theranostics; 2015; 5(2):124-33. PubMed ID: 25553103
[TBL] [Abstract][Full Text] [Related]
7. Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.
Winter PM; Neubauer AM; Caruthers SD; Harris TD; Robertson JD; Williams TA; Schmieder AH; Hu G; Allen JS; Lacy EK; Zhang H; Wickline SA; Lanza GM
Arterioscler Thromb Vasc Biol; 2006 Sep; 26(9):2103-9. PubMed ID: 16825592
[TBL] [Abstract][Full Text] [Related]
8. Transferrin-Targeted Nanoparticles Containing Zoledronic Acid as a Potential Tool to Inhibit Glioblastoma Growth.
Salzano G; Zappavigna S; Luce A; D'Onofrio N; Balestrieri ML; Grimaldi A; Lusa S; Ingrosso D; Artuso S; Porru M; Leonetti C; Caraglia M; De Rosa G
J Biomed Nanotechnol; 2016 Apr; 12(4):811-30. PubMed ID: 27301207
[TBL] [Abstract][Full Text] [Related]
9. High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model.
Lijowski M; Caruthers S; Hu G; Zhang H; Scott MJ; Williams T; Erpelding T; Schmieder AH; Kiefer G; Gulyas G; Athey PS; Gaffney PJ; Wickline SA; Lanza GM
Invest Radiol; 2009 Jan; 44(1):15-22. PubMed ID: 18836386
[TBL] [Abstract][Full Text] [Related]
10. Zoledronic acid in combination with serine/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A.
Cirak Y; Varol U; Atmaca H; Kisim A; Sezgin C; Karabulut B; Uzunoglu S; Uslu R; Karaca B
BJU Int; 2012 Dec; 110(11 Pt C):E1147-54. PubMed ID: 22882676
[TBL] [Abstract][Full Text] [Related]
11. Glutathione- and pH-responsive nonporous silica prodrug nanoparticles for controlled release and cancer therapy.
Xu Z; Liu S; Kang Y; Wang M
Nanoscale; 2015 Mar; 7(13):5859-68. PubMed ID: 25757484
[TBL] [Abstract][Full Text] [Related]
12. Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.
Winter PM; Schmieder AH; Caruthers SD; Keene JL; Zhang H; Wickline SA; Lanza GM
FASEB J; 2008 Aug; 22(8):2758-67. PubMed ID: 18362202
[TBL] [Abstract][Full Text] [Related]
13. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
14. New self-assembly nanoparticles and stealth liposomes for the delivery of zoledronic acid: a comparative study.
Marra M; Salzano G; Leonetti C; Porru M; Franco R; Zappavigna S; Liguori G; Botti G; Chieffi P; Lamberti M; Vitale G; Abbruzzese A; La Rotonda MI; De Rosa G; Caraglia M
Biotechnol Adv; 2012; 30(1):302-9. PubMed ID: 21741464
[TBL] [Abstract][Full Text] [Related]
15. Infra Red Dye and Endostar Loaded Poly Lactic Acid Nano Particles as a Novel Theranostic Nanomedicine for Breast Cancer.
Zhang Q; Du Y; Jing L; Liang X; Li Y; Li X; Dai Z; Tian J
J Biomed Nanotechnol; 2016 Mar; 12(3):491-502. PubMed ID: 27280247
[TBL] [Abstract][Full Text] [Related]
16. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.
Winter PM; Caruthers SD; Zhang H; Williams TA; Wickline SA; Lanza GM
JACC Cardiovasc Imaging; 2008 Sep; 1(5):624-34. PubMed ID: 19356492
[TBL] [Abstract][Full Text] [Related]
17. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
[TBL] [Abstract][Full Text] [Related]
18. Small Molecule MYC Inhibitor Conjugated to Integrin-Targeted Nanoparticles Extends Survival in a Mouse Model of Disseminated Multiple Myeloma.
Soodgupta D; Pan D; Cui G; Senpan A; Yang X; Lu L; Weilbaecher KN; Prochownik EV; Lanza GM; Tomasson MH
Mol Cancer Ther; 2015 Jun; 14(6):1286-1294. PubMed ID: 25824336
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging.
Winter PM; Caruthers SD; Kassner A; Harris TD; Chinen LK; Allen JS; Lacy EK; Zhang H; Robertson JD; Wickline SA; Lanza GM
Cancer Res; 2003 Sep; 63(18):5838-43. PubMed ID: 14522907
[TBL] [Abstract][Full Text] [Related]
20. Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial.
James ND; Pirrie SJ; Pope AM; Barton D; Andronis L; Goranitis I; Collins S; Daunton A; McLaren D; O'Sullivan J; Parker C; Porfiri E; Staffurth J; Stanley A; Wylie J; Beesley S; Birtle A; Brown J; Chakraborti P; Hussain S; Russell M; Billingham LJ
JAMA Oncol; 2016 Apr; 2(4):493-9. PubMed ID: 26794729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
